In patients with Parkinson's disease, heterogeneous cholinergic system changes can occur
in different brain regions. These changes correlate with a range of clinical features, both …

Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …

Thanks to its safety and accessibility, magnetic resonance imaging (MRI) is extensively used
in clinical routine and research field, largely contributing to our understanding of the …

Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

Amyloid-beta (Aß) and hyperphosphorylated tau are hallmark lesions of Alzheimer's disease
(AD). However, the loss of synapses and dysfunctions of neurotransmission are more …

In the long-term, with progression of the illness, Parkinson's disease dementia affects up to
90% of patients with Parkinson's disease. With increasing life expectancy in western …

The elderly population is growing worldwide, with important health and socioeconomic
implications. Clinical and experimental studies on aging have uncovered numerous …

Neurodegenerative diseases are characterized by the progressive functional loss of
neurons in the brain, causing cognitive impairment and motoneuron disability. Although …

The basal forebrain cholinergic complex comprising medial septum, horizontal and vertical
diagonal band of Broca, and nucleus basalis of Meynert provides the mayor cholinergic …

Research into the heterogeneous nature of cognitive impairment documented in patients
with Parkinson's disease (PD) has focused on disentangling deficits that vary between …